Publication Author: Udell JA
Filter by Author:
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis.
Lok CE, Farkouh M, Hemmelgarn BR, Moist LM, Polkinghorne KR, Tomlinson G, Tam P, Tonelli M, Udell JA; PISCES Investigators.
FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial.
Punithan A, Ghamarian E, Grothe D, MacLean M, Connelly K, Neal B, Weisman A, Cherney DZI, Billia F, Udell JA.
Vaccination in Patients with Cardiovascular Disease: A Case-Based Approach and Contemporary Review.
Sedrak P, Dounaevskaia V, Mancini GBJ, Zieroth S, McKelvie RS, Chiu W, Bewick D, Ducharme A, Mansour S, Lepage S, Pearson GJ, Welsh RC, Udell JA, Connelly KA.
Uptake of Goal-Directed Therapies in a Multidisciplinary and Interdisciplinary Cardiology-Renal-Endocrine Clinic: A Research Letter.
Ouimet JP, Mohsen M, Ni H, Weisman A, Udell JA, Cherney DZI.
Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: Insights from EMPACT-MI.
Fioretti F, Butler J, Udell JA, Schuyler Jones W, Petrie MC, Harrington J, Mattheus M, Bauersachs J, Bayes-Genis A, Goodman SG, Gasior T, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, van der Meer P, Vinereanu D, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Anker SD.
Real-world effectiveness of early revascularization in stable coronary artery disease with moderate or severe ischemia.
Gerodias FJ, Iwanochko RM, Austin PC, Wang X, Džavík V, Goodman SG, Udell JA, Ouzounian M, Ross HJ, Godoy LC, Amad H, Husain M, Lee DS.
Educational Attainment Level and Risk of Mortality and Cardiopulmonary Outcomes in High-Risk Patients With Cardiovascular Disease: The INVESTED Trial
Lassen MCH, Howell N, Claggett BL, Biering-Sørensen T, Vardeny O, Solomon SD, Udell J, Joseph J, Hegde SM.
Prevention of heart failure after acute myocardial infarction.
Udell JA, Bahit MC, Campbell P, Butler J, Chopra VK, Bayés-Genís A, Bozkurt B, Petrie MC, Vaduganathan M.
Association between dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists and COVID-19 infection and adverse outcomes: a cohort study.
Thompson W, Yu B, Porter J, Fang J, Ferreira-Legere LE, Austin PC, Jackevicius CA, Ross H, Lee DS, Weisman A, Farkouh ME, Gershon AS, Atzema CL, Kwong JC, Ha A, Džavík V, Udell JA.
Blinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF Trial.
Vaduganathan M, Claggett BL, Udell JA, Desai AS, Jhund PS, Henderson AD, Lay-Flurrie J, Amarante F, Glasauer A, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, McMurray JJV, Solomon SD.
Cholesterol Levels and Cardiovascular Outcomes Following Statin Initiation for Primary Prevention: A Cohort Study.
Thompson W, Jeong I, Basque S, Abdel-Qadir H, Austin PC, Ko DT, Famiyeh I, Chu A, Fang J, Odutayo A, Jackevicius CA, Godoy LC, Lee DS, Anderson TJ, Udell JA.
The Effect of an Incentive Billing Code on Heart Failure Management in Primary Care: A Population-Based Study
Zhou S, Lee DS, Nguyen F, Benipal H, Perez R, Austin PC, Abdel-Qadir H, Udell JA, Demers C
Acidocétose diabétique causée par un inhibiteur du cotransporteur sodium-glucose de type 2 chez un homme de 28 ans sans antécédents de diabète.
Cho S, Mak J, Udell JA, Gold WL, Weisman A.
Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Emergency Department Visits and Hospitalization in Patients With Chronic Kidney Disease.
Yau K, Ray JG, Jeyakumar N, Luo B, Abdullah S, McArthur E, Dixon SN, Wing S, Clemens KK, Castrillon-Ramirez F, Udell JA, Meraz-Munoz A, Young A, Harel Z, Perl J, Sridhar VS, Ni H, Yi TW, Leiter LA, Garg AX, Cherney DZI, Wald R.
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarction.
Aggarwal R, Bhatt DL, Hernandez AF, Anker SD, Harrington J, Jones WS, Mattheus M, Petrie MC, Steubl D, Sumin M, Thanam V, Udell JA, Butler J.
High Time for High-Dose Flu Vaccines in Cardiovascular Patients?
Behrouzi B, Udell JA.
Sodium-Glucose Cotransporter 2 Inhibitors Preceding ST-Segment Elevation Myocardial Infarction: Global Proteomics and Pathobiological Insights
Shavadia JS, Tomilin M, Chumala P, Mangipudi R, Udell J, Haddad H, Katselis GS.
Uptake of novel evidence-based therapies in patients with type 2 diabetes after a cardiovascular event: insights from CANHEART
Wade Thompson, Brendan Wong, Atul Sivaswamy, Laura Ferreira-Legere, Douglas S. Lee, Husam Abdel-Qadir, Dennis T. Ko, Alanna Weisman, Sheldon Tobe, Cynthia A. Jackevicius, Shaun G. Goodman, Michael E. Farkouh, Jacob A. Udell
Diabetic ketoacidosis induced by a sodium-glucose cotransporter-2 inhibitor in a 28-year-old man without known diabetes.
Cho S, Mak J, Udell JA, Gold WL, Weisman A.
Risk of Heart Failure in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Study.
Koppikar S, Kuriya B, Udell JA, Yu B, Chu A, Lee DS, Widdifield J, Eder L.
